A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine

TITLE:

MEDICAL CONTION:

AGE:

SEX/GENDER:

Overview

Study Details